SCHEMBL17025698

SCHEMBL17025698

Cn1c(=O)c(-c2ccccc2Cl)cc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.54
KDM4E B2RXH2 5/20 0.47
KMT2A Q03164 3/20 0.47
FGFR1 P11362 3/20 0.46
SRC P12931 3/20 0.46
HPGD P15428 3/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
LCK P06239 1/20 0.44
MAPK14 Q16539 1/20 0.44
KLK7 P49862 1/20 0.44
CA12 O43570 1/20 0.43
BRD4 O60885 1/20 0.43
BRPF1 P55201 1/20 0.43
CA9 Q16790 1/20 0.43
KAT2B Q92831 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30740092 1.00 DAO (0.54) DAOKDM4EKMT2AFGFR1SRC
SCHEMBL28165616 0.81 DAO (0.62) DAOKDM4EKMT2AHPGDLMNA
SCHEMBL11303565 0.81 DAO (0.68) DAOKDM4EKMT2AHPGDLMNA
SCHEMBL8507229 0.81 PDE2A (0.46) DAOKDM4EKMT2AHPGDLMNA
SCHEMBL21990261 0.80 FGFR1 (0.58) FGFR1SRCLCKMAPK14ABL1
SCHEMBL10757723 0.78 DAO (0.59) DAOKDM4EKMT2AHPGDLMNA
SCHEMBL28259492 0.78 KMT2A (0.65) DAOKDM4EKMT2AHPGDALDH1A1
SCHEMBL5037218 0.76 WEE1 (0.56) DAOKDM4EKMT2AFGFR1SRC
SCHEMBL2977751 0.73 KMT2A (0.47) DAOKDM4EKMT2AHPGDLMNA
SCHEMBL18536886 0.73 DAO (0.61) DAOKDM4EKMT2AHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464055-B2 Quinoline derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2016-10-11 US disclosed
US-20150239845-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed
US-20150239844-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239844-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, CNR2, GPR119 DAO 3217/4885KDM4E 3552/4885KMT2A 3398/4885
US-20150239845-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, CNR2, GPR119 DAO 3217/4885KDM4E 3552/4885KMT2A 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.